title: What justifies a placebo-controlled trial of Varenicline for smoking cessation in patients with COPD?
authors.affiliation: Department of General Practice, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, The Netherlands. Electronic address: d.kotz@maastrichtuniversity.nl.
authors.forename: Daniel
authors.initials: D
authors.lastname: Kotz
authors.affiliation: Department of General Practice, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, The Netherlands.
authors.forename: Onno C P
authors.initials: OCP
authors.lastname: van Schayck
mesh_terms: D001552:Benzazepines / Q000627:therapeutic use*; D006801:Humans; D018722:Nicotinic Agonists / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications*; D011810:Quinoxalines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012907:Smoking / Q000009:adverse effects; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention; D016896:Treatment Outcome; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D000068580:Varenicline